Analysts Set Haemonetics Corporation (NYSE:HAE) Price Target at $78.33

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $78.3333.

HAE has been the subject of several recent analyst reports. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. JPMorgan Chase & Co. decreased their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research report on Friday. Finally, Citigroup boosted their target price on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, May 28th.

Haemonetics Stock Performance

Shares of HAE stock opened at $77.34 on Wednesday. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The stock has a market cap of $3.51 billion, a PE ratio of 38.29, a price-to-earnings-growth ratio of 1.56 and a beta of 0.55. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company’s fifty day moving average price is $65.41 and its 200-day moving average price is $66.76.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, equities analysts expect that Haemonetics will post 5.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Haemonetics during the 1st quarter valued at about $216,000. United Services Automobile Association purchased a new stake in shares of Haemonetics during the 1st quarter valued at about $212,000. Empowered Funds LLC increased its position in shares of Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.